Literature DB >> 10415059

Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously.

S W Dow1, L G Fradkin, D H Liggitt, A P Willson, T D Heath, T A Potter.   

Abstract

Cationic lipid-DNA complexes (CLDC) are reported to be safe and effective for systemic gene delivery, particularly to the lungs. However, we observed that i.v. injection of CLDC induced immunologic effects not previously reported. We found that even very low doses of CLDC administered i.v. induced marked systemic immune activation. This response included strong up-regulation of CD69 expression on multiple cell types and systemic release of high levels of Th1 cytokines, from both lung and spleen mononuclear cells. CLDC were much more potent immune activators on a per weight basis than either LPS or poly(I:C). The remarkable potency of CLDC appeared to result from enhancement of the immune stimulatory properties of DNA, since cationic lipids alone were without immune stimulatory activity. Systemic treatment with CLDC controlled tumor growth and significantly prolonged survival times in mice with metastatic pulmonary tumors. NK cells accumulated to high levels in the lungs of CLDC-treated mice, were functionally activated, and released high levels of IFN-gamma. The antitumor activity induced by CLDC injection was dependent on both NK cells and IFN-gamma. Thus, DNA complexed to cationic liposomes becomes highly immunostimulatory and capable of inducing strong antitumor activity when administered systemically.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10415059

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  61 in total

Review 1.  In vivo characteristics of cationic liposomes as delivery vectors for gene therapy.

Authors:  Sandrine A L Audouy; Lou F M H de Leij; Dick Hoekstra; Grietje Molema
Journal:  Pharm Res       Date:  2002-11       Impact factor: 4.200

2.  Treatment with cationic liposome-DNA complexes (CLDCs) protects mice from lethal Western equine encephalitis virus (WEEV) challenge.

Authors:  Christopher H Logue; Aaron T Phillips; Eric C Mossel; Jeremy P Ledermann; Thomas Welte; Steve W Dow; Ken E Olson; Ann M Powers
Journal:  Antiviral Res       Date:  2010-05-07       Impact factor: 5.970

3.  Peptides containing antigenic and cationic domains have enhanced, multivalent immunogenicity when bound to DNA vaccines.

Authors:  Petra Riedl; Jörg Reimann; Reinhold Schirmbeck
Journal:  J Mol Med (Berl)       Date:  2003-12-02       Impact factor: 4.599

Review 4.  Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection.

Authors:  Crispin R Dass
Journal:  J Mol Med (Berl)       Date:  2004-06-23       Impact factor: 4.599

5.  Transient depletion of kupffer cells leads to enhanced transgene expression in rat liver following retrograde intrabiliary infusion of plasmid DNA and DNA nanoparticles.

Authors:  Hui Dai; Xuan Jiang; Kam W Leong; Hai-Quan Mao
Journal:  Hum Gene Ther       Date:  2011-03-04       Impact factor: 5.695

6.  A non-coding cationic lipid DNA complex produces lasting anti-leukemic effects.

Authors:  Nikki Keasey; Zachary Herse; Stella Chang; Denny H Liggitt; Marla Lay; Jeffery Fairman; David F Claxton
Journal:  Cancer Biol Ther       Date:  2010-09-13       Impact factor: 4.742

7.  Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection.

Authors:  Katie L Propst; Ryan M Troyer; Lisa M Kellihan; Herbert P Schweizer; Steven W Dow
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

Review 8.  Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells.

Authors:  Shaw-Wei D Tsen; Augustine H Paik; Chien-Fu Hung; T-C Wu
Journal:  Expert Rev Vaccines       Date:  2007-04       Impact factor: 5.217

9.  Protection from pneumonic infection with burkholderia species by inhalational immunotherapy.

Authors:  Andrew Goodyear; Lisa Kellihan; Helle Bielefeldt-Ohmann; Ryan Troyer; Katie Propst; Steven Dow
Journal:  Infect Immun       Date:  2009-01-29       Impact factor: 3.441

10.  Optimized dosing of a CCR2 antagonist for amplification of vaccine immunity.

Authors:  Leah A Mitchell; Ryan J Hansen; Adam J Beaupre; Daniel L Gustafson; Steven W Dow
Journal:  Int Immunopharmacol       Date:  2012-12-13       Impact factor: 4.932

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.